Novartis AG
NVS
Company Profile
Business description
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Contact
Lichtstrasse 35
Basel4056
CHET: +41 613241111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
76,057
Novartis AG News & Analysis
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks
Best international companies to own: 2023 Edition
These companies from various corners of the globe are well positioned for the future.
markets
Asian markets are globalising
In an era of onshoring and localisation, revenue sources show an increasingly interconnected world economy
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,708.50 | 46.20 | -0.53% |
| CAC 40 | 7,255.42 | 18.53 | 0.26% |
| DAX 40 | 20,016.75 | 83.13 | 0.42% |
| Dow JONES (US) | 44,705.53 | 76.47 | -0.17% |
| FTSE 100 | 8,359.41 | 46.52 | 0.56% |
| HKSE | 19,641.62 | 104.70 | -0.53% |
| NASDAQ | 19,480.91 | 76.96 | 0.40% |
| Nikkei 225 | 39,172.60 | 76.26 | -0.19% |
| NZX 50 Index | 12,895.20 | 197.98 | -1.51% |
| S&P 500 | 6,049.88 | 2.73 | 0.05% |
| S&P/ASX 200 | 8,442.60 | 52.60 | -0.62% |
| SSE Composite Index | 3,365.75 | 13.06 | -0.39% |